Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients

NCT03437083 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.

NCT NCT03437083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03437083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients
Lead sponsor
Eisai Korea Inc.
Phase
Observational
Overall status
Completed
Start date
January 25, 2018
Completion date
June 30, 2018
Enrollment
340 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic breast cancer